Please provide your email address to receive an email when new articles are posted on . Pelabresib plus ruxolitinib conferred benefit to Janus kinase inhibitor-naive patients with myelofibrosis, ...

Findings of MANIFEST-2 show “valuable evidence that the addition of pelabresib offers meaningful improvements over JAK inhibitor monotherapy as a first-line approach for patients with myelofibrosis,” ...

Pain under your left rib cage isn't uncommon, but figuring out the culprit can take some trial and error. The left side under the ribs is home to several major organs ...

Aaron T. Gerds, MD, MS, spoke with Healio about the randomized phase 3 MOMENTUM study. Researchers compared momelotinib (Sierra Oncology) — an oral ACVR1/ALK2 and JAK1/JAK2 inhibitor — with danazol ...

Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed. Patients with myelofibrosis who ...

John Mascarenhas, MD, director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, spoke on preliminary data findings of the phase 2 MANIFEST study investigating the efficacy ...

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according ...

Indian cricket's ODI vice-captain Shreyas Iyer is in Sydney's ICU after suffering a spleen laceration during a match against Australia. The injury occurred while taking a catch, leading to internal ...